CD274 and breast cancer: Meanwhile, TNBC patients with higher levels of PD-L1 expression, tumor mutation burden (TMB), and tumor-infiltrating lymphocytes may be more likely to benefit from ICI therapy compared to patients with other BC subtypes (5, 20).